PEMF for
Sjögren's Syndrome.

August 2026 · 10 min read · Autoimmune Protocol

Sjögren's Syndrome: A Systemic Autoimmune Condition

Sjögren's syndrome (SS) is a chronic systemic autoimmune disorder in which autoreactive lymphocytes target exocrine glands — primarily salivary and lacrimal — producing the hallmark symptoms of dry mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca). But SS is far more than a secretory gland disease: extraglandular manifestations affect up to 70% of patients and include arthralgia, myalgia, peripheral neuropathy, fatigue, and in severe cases, pulmonary and renal involvement.

SS affects an estimated 0.5–3% of the global population, with 90% of cases occurring in women. It is classified as primary SS (no underlying connective tissue disease) or secondary SS (coexisting with rheumatoid arthritis, lupus, or systemic sclerosis). Up to 30–50% of primary SS patients develop peripheral neuropathy — including small fiber neuropathy, sensory ataxic neuropathy, and mononeuropathy multiplex — making it one of the most neurologically active autoimmune conditions encountered in musculoskeletal practice.

The Multi-System Pain Burden in Sjögren's

ESSPRI (European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) quantifies three core symptom domains: dryness, fatigue, and pain. PEMF's evidence base addresses primarily the pain and fatigue domains through concurrent anti-inflammatory and neuromodulatory mechanisms:

• Arthralgia and myalgia — present in 40–70% of SS patients; often polyarticular and symmetrical, resembling RA but seronegative for anti-CCP
• Peripheral neuropathy — burning, tingling, or numbness in a stocking-glove or patchy distribution; 30–50% prevalence in primary SS
• Fatigue — severe and disabling in 70%+ of patients; driven by neuroinflammation, mitochondrial dysfunction, and autonomic dysregulation
• Fibromyalgia overlap — 22–30% of SS patients meet fibromyalgia criteria, requiring central sensitization-targeted treatment

Four PEMF Mechanisms Relevant to Sjögren's

1. Th1/Th2/Th17 cytokine suppression — PEMF at 8–25 Hz activates adenosine-A2A receptors on T-lymphocytes, suppressing IL-6, IL-17, TNF-α, and IFN-γ production. These are the same cytokines driving lymphocytic infiltration of exocrine glands and synovial inflammation in SS.
2. Salivary gland secretomotor modulation — voltage-gated Ca²⁺ channel modulation at 25–50 Hz can enhance parasympathetic acetylcholine release at salivary acinar cells, supporting residual secretory function in glands not yet completely destroyed by lymphocytic infiltration.
3. Small fiber neuropathy reversal — PEMF-induced BDNF upregulation and mitochondrial membrane potential restoration (PMC11874150, RELIEF trial n=182) act on intraepidermal nerve fiber density, the primary pathological marker of SS-associated small fiber neuropathy.
4. Fatigue via mitochondrial ATP restoration — PEMF's documented ATP upregulation in mitochondria (Bassett et al., validated in multiple RCTs) directly addresses the cellular energy deficit driving SS fatigue, independent of the immunological axis.

Clinical Evidence Base

Clinical Protocol: Three-Phase Approach

Phase 1 — Systemic Anti-Inflammatory (Weeks 1–4, 3× weekly)

• Frequency: 8–25 Hz
• Coil placement: Rotational — major symptomatic joint(s) + paravertebral for systemic cytokine modulation
• Session duration: 35–40 minutes
• Goal: Suppress Th1/Th17 cytokine cascade; reduce arthralgia and myalgia; improve functional capacity

Phase 2 — Neuropathy & Fatigue Targeting (Weeks 5–8, 2× weekly)

• Frequency: 25–50 Hz
• Coil placement: Peripheral — affected limb segments + lumbar/sacral for autonomic support; parotid region (optional, low-intensity) for salivary support
• Session duration: 30–35 minutes
• Goal: Neuromodulation for small fiber neuropathy; BDNF upregulation; mitochondrial ATP restoration for fatigue

Phase 3 — Maintenance (Ongoing, 1–2× weekly)

• Frequency: 8–50 Hz (symptom-guided)
• Goal: Sustain remission; support glandular function; prevent neuropathy progression
• Monitoring: ESSPRI at baseline, month 2, month 6; nerve conduction study or Sudoscan at 6 months if neuropathy present

Sjögren's Symptom Clusters and PEMF Response Profiles

Philippines Market Context

Sjögren's syndrome is one of the most prevalent yet underdiagnosed autoimmune conditions in the Philippines. An estimated 500,000–1.5 million Filipinos live with primary or secondary SS — most diagnosed only after years of fragmented care across ophthalmology, dentistry, rheumatology, and neurology. The rheumatology workforce is critically inadequate: fewer than 300 rheumatologists serve a population of 115 million, with the majority concentrated in Metro Manila.

Standard-of-care treatments carry significant cost and access barriers: hydroxychloroquine costs ₱2,000–₱5,000/month; rituximab infusions run ₱80,000–₱150,000 per cycle; cyclosporine eye drops for keratoconjunctivitis are ₱4,000–₱8,000/month. The neuropathy component is almost universally undertreated — gabapentin is prescribed but poorly tolerated, and intravenous immunoglobulin (IVIG) for severe SS neuropathy costs ₱50,000–₱120,000 per infusion.

This treatment gap — a large, underserved autoimmune population with multi-system pain and fatigue but limited access to effective, affordable therapies — represents a direct market opportunity for PEMF clinic investment. At 70+ Israeli clinics (population: 9M) now expanding to the Philippines, SS is positioned as a protocol generating recurring visits (16–24+ sessions per patient) with strong adherence driven by symptom relief.

Contraindications and Precautions

• Absolute: Active pacemaker or ICD; active malignancy in the treatment field — critical note: SS carries a 5× increased risk of non-Hodgkin lymphoma (NHL); mandatory oncology screening before initiating treatment
• Relative (specialist clearance required): Known or suspected SS-associated lymphoma (parotid swelling, B-symptoms, LAP — refer to haematology); pulmonary SS involvement with severe interstitial lung disease; renal SS involvement
• Safety note: PEMF does not treat the underlying autoimmune process. Hydroxychloroquine or other disease-modifying therapy should continue; PEMF is an adjunct for symptom management, not a disease-modifying agent
• Ophthalmology coordinate: Parotid zone application — obtain ophthalmology clearance if patient has corneal complications of keratoconjunctivitis sicca

What This Means for Clinic Investors

Sjögren's syndrome creates a recurring-revenue patient profile that is ideal for PEMF clinic economics. These patients have multiple concurrent symptoms (arthralgia, neuropathy, fatigue) requiring ongoing management rather than time-limited acute care. They are typically working-age women (peak onset 40–60 years) with healthcare purchasing power and strong motivation to avoid systemic immunosuppression side effects.

The autoimmune protocol position also creates referral relationships with rheumatologists and neurologists — high-value professional networks that drive consistent patient flow without direct-to-consumer marketing spend. At ₱1,500–₱2,500 per session and 20–30 sessions per annual treatment cycle, each committed SS patient generates ₱30,000–₱75,000 in annual recurring clinic revenue.